Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans

Frontiers in Pharmacology

Volumn 5, Issue DEC, 2014, Pages

  Lu, Yasong ^a   Griffen, Steven C ^a,b   Boulton, David W ^a   Leil, Tarek A ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b JDRF   (United States)

Author keywords

Dapagliflozin; Diabetes mellitus; Glucosuria; Renal glucose reabsorption; SGLT; Systems pharmacology model

Indexed keywords

DAPAGLIFLOZIN; GLUCOSE; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;

ARTICLE; CALIBRATION; CONTROLLED STUDY; DATA ANALYSIS; DRUG POTENCY; FUNCTIONAL ASSESSMENT; GENE MAPPING; GLUCOSE ABSORPTION; GLUCOSE TOLERANCE TEST; GLUCOSE URINE LEVEL; GLYCEMIC CONTROL; HUMAN; IN VIVO STUDY; KIDNEY FUNCTION; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MOLECULAR DYNAMICS; OUTCOME ASSESSMENT; PREDICTION; PROCESS DEVELOPMENT; PROCESS MODEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SYSTEM PHARMACOLOGY MODEL;

EID: 84921788614     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00274     Document Type: Article

References (47)

1. Abdul-Ghani, M. A., DeFronzo, R. A., and Norton, L. (2013). Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Diabetes 62, 3324-3328. doi: 10.2337/db13-0604
2. Bank, N., and Aynedjian, H. S. (1990). Progressive increases in luminal glucose stimulate proximal sodium absorption in normal and diabetic rats. J. Clin. Invest. 86, 309-316. doi: 10.1172/JCI114700
3. Brown, B. P., Hawley, H. B., and Hessen, M. T. (2011). Magill's Medical Guide, Vol. 3: Fluids and Electrolytes-Kidneys. Pasadena, CA: Salem Press, Incorporated.
4. Calado, J., Sznajer, Y., Metzger, D., Rita, A., Hogan, M. C., Kattamis, A., et al. (2008). Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion. Nephrol. Dial. Transplant. 23, 3874-3879. doi: 10.1093/ndt/gfn386
5. Chao, E. C., and Henry, R. R. (2010). SGLT2 inhibition-a novel strategy for diabetes treatment. Nat. Rev. Drug. Discov. 9, 551-559. doi: 10.1038/nrd3180
6. DeFronzo, R. A., Davidson, J. A., and Del Prato, S. (2012). The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes. Metab. 14, 5-14. doi: 10.1111/j.1463-1326.2011.01511.x
7. DeFronzo, R. A., Hompesch, M., Kasichayanula, S., Liu, X., Hong, Y., Pfister, M., et al. (2013). Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care 36, 3169-3176. doi: 10.2337/dc13-0387
8. Devineni, D., Curtin, C. R., Polidori, D., Gutierrez, M. J., Murphy, J., Rusch, S., et al. (2013). Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J. Clin. Pharmacol. 53, 601-610. doi: 10.1002/jcph.88
9. Diez-Sampedro, A., Wright, E. M., and Hirayama, B. A. (2001). Residue 457 controls sugar binding and transport in the Na(+)/glucose cotransporter. J. Biol. Chem. 276, 49188-49194. doi: 10.1074/jbc. M108286200
10. Freckmann, G., Hagenlocher, S., Baumstark, A., Jendrike, N., Gillen, R. C., Rossner, K., et al. (2007). Continuous glucose profiles in healthy subjects under everyday life conditions and after different meals. J. Diabetes Sci. Technol. 1, 695-703. doi: 10.1177/193229680700100513
11. Freitas, H. S., Anhe, G. F., Melo, K. F., Okamoto, M. M., Oliveira-Souza, M., Bordin, S., et al. (2008). Na(+) -glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity. Endocrinology 149, 717-724. doi: 10.1210/en.2007-1088
12. Gorboulev, V., Schurmann, A., Vallon, V., Kipp, H., Jaschke, A., Klessen, D., et al. (2012). Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 61, 187-196. doi: 10.2337/db11-1029
13. Grempler, R., Thomas, L., Eckhardt, M., Himmelsbach, F., Sauer, A., Sharp, D. E., et al. (2012). Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes. Metab. 14, 83-90. doi: 10.1111/j.1463-1326.2011.01517.x
14. Haddish-Berhane, N., Nucci, G., Sawant, A., Maurer, T. S., and Ghosh, A. (2010). "A minimal systems pharmacology model of SGLT2/SGLT1 glucose uptake and transport with applications to SGLT2 inhibitors," in Poster Presentation at the 6th International Symposium on Measurement and Kinetics of In Vivo Drug Effects (Noordwijkerhout).
15. Heise, T., Seewaldt-Becker, E., Macha, S., Hantel, S., Pinnetti, S., Seman, L., et al. (2013). Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes. Metab. 15, 613-621. doi: 10.1111/dom.12073
16. +/D-glucose cotransporters SGLT1 and SGLT2. Am. J. Physiol. Cell Physiol. 300, C14-C21. doi: 10.1152/ajpcell.00388.2010
17. Kleta, R., Stuart, C., Gill, F. A., and Gahl, W. A. (2004). Renal glucosuria due to SGLT2 mutations. Mol. Genet. Metab. 82, 56-58. doi: 10.1016/j.ymgme.2004.01.018
18. Koeppen, B. M., and Stanton, B. A. (2013). "Chapter 4-renal transport mechanisms: NaCl and water reabsorption along the nephron," in Renal Physiology, 5th Edn., eds B. M. Koeppen and B. A. Stanton (Philadelphia, PA: Mosby), 45-71.
19. Komoroski, B., Vachharajani, N., Boulton, D., Kornhauser, D., Geraldes, M., Li, L., et al. (2009a). Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin. Pharmacol. Ther. 85, 520-526. doi: 10.1038/clpt.2008.251
20. Komoroski, B., Vachharajani, N., Feng, Y., Li, L., Kornhauser, D., and Pfister, M. (2009b). Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin. Pharmacol. Ther. 85, 513-519. doi: 10.1038/clpt.2008.250
21. Lam, J. T., Martin, M. G., Turk, E., Hirayama, B. A., Bosshard, N. U., Steinmann, B., et al. (1999). Missense mutations in SGLT1 cause glucose-galactose malabsorption by trafficking defects. Biochim. Biophys. Acta 1453, 297-303. doi: 10.1016/S0925-4439(98)00109-4
22. Liu, J. J., Lee, T., and DeFronzo, R. A. (2012). Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes 61, 2199-2204. doi: 10.2337/db12-0052
23. Lu, Y., Griffen, S. C., Boulton, D., Lacreta, F., and Leil, T. (2014). "A systems pharmacology model of renal glucose physiology to evaluate the effects of SGLT1 and SGLT2 inhibition in T1DM subjects," in American Conference on Pharmacometrics (Las Vegas, NV).
24. Martin, M. G., Turk, E., Lostao, M. P., Kerner, C., and Wright, E. M. (1996). Defects in Na+/glucose cotransporter (SGLT1) trafficking and function cause glucose-galactose malabsorption. Nat. Genet. 12, 216-220. doi: 10.1038/ng0296-216
25. Mather, A., and Pollock, C. (2011). Glucose handling by the kidney. Kidney Int. Suppl. 79(Suppl. 120), S1-S6. doi: 10.1038/ki.2010.509
26. Maurer, T. S., Ghosh, A., Haddish-Berhane, N., Sawant-Basak, A., Boustany-Kari, C. M., She, L., et al. (2011). Pharmacodynamic model of sodium-glucose transporter 2 (SGLT2) inhibition: implications for quantitative translational pharmacology. AAPS J. 13, 576-584. doi: 10.1208/s12248-011-9297-2
27. Mogensen, C. E. (1971). Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand. J. Clin. Lab. Invest. 28, 101-109. doi: 10.3109/00365517109090668
28. Moller, J. C., and Skriver, E. (1985). Quantitative ultrastructure of human proximal tubules and cortical interstitium in chronic renal disease (hydronephrosis). Virchows Arch. A Pathol. Anat. Histopathol. 406, 389-406. doi: 10.1007/BF00710231
29. Pfister, M., Whaley, J. M., Zhang, L., and List, J. F. (2011). Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus. Clin. Pharmacol. Ther. 89, 621-625. doi: 10.1038/clpt.2011.16
30. Polidori, D., Sha, S., Ghosh, A., Plum-Morschel, L., Heise, T., and Rothenberg, P. (2013). Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 98, E867-E871. doi: 10.1210/jc.2012-4205
31. Powell, D. R., Dacosta, C. M., Gay, J., Ding, Z. M., Smith, M., Greer, J., et al. (2013). Improved glycemic control in mice lacking Sglt1 and Sglt2. Am. J. Physiol. Endocrinol. Metab. 304, E117-E130. doi: 10.1152/ajpendo.00439.2012
32. Rahmoune, H., Thompson, P. W., Ward, J. M., Smith, C. D., Hong, G., and Brown, J. (2005). Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54, 3427-3434. doi: 10.2337/diabetes.54.12.3427
33. Rieg, T., Masuda, T., Gerasimova, M., Mayoux, E., Platt, K., Powell, D. R., et al. (2014). Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am. J. Physiol. Renal. Physiol. 306, F188-F193. doi: 10.1152/ajprenal.00518.2013
34. Santer, R., Kinner, M., Lassen, C. L., Schneppenheim, R., Eggert, P., Bald, M., et al. (2003). Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J. Am. Soc. Nephrol. 14, 2873-2882. doi: 10.1097/01.ASN.0000092790.89332.D2
35. Tabatabai, N. M., Sharma, M., Blumenthal, S. S., and Petering, D. H. (2009). Enhanced expressions of sodium-glucose cotransporters in the kidneys of diabetic Zucker rats. Diabetes Res. Clin. Pract. 83, e27-e30. doi: 10.1016/j.diabres.2008.11.003
36. Thelwall, P. E., Taylor, R., and Marshall, S. M. (2011). Non-invasive investigation of kidney disease in type 1 diabetes by magnetic resonance imaging. Diabetologia 54, 2421-2429. doi: 10.1007/s00125-011-2163-z
37. Vallon, V. (2011). Molecular determinants of renal glucose reabsorption. Focus on "Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2." Am. J. Physiol. Cell Physiol. 300, C6-C8. doi: 10.1152/ajpcell.00444.2010
38. Vallon, V., Gerasimova, M., Rose, M. A., Masuda, T., Satriano, J., Mayoux, E., et al. (2014). SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am. J. Physiol. Renal. Physiol. 306, F194-F204. doi: 10.1152/ajprenal.00520.2013
39. Vallon, V., Platt, K. A., Cunard, R., Schroth, J., Whaley, J., Thomson, S. C., et al. (2011). SGLT2 mediates glucose reabsorption in the early proximal tubule. J. Am. Soc. Nephrol. 22, 104-112. doi: 10.1681/ASN.2010030246
40. Vallon, V., and Thomson, S. C. (2012). Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. Annu. Rev. Physiol. 74, 351-375. doi: 10.1146/annurev-physiol-020911-153333
41. Washburn, W. N., and Poucher, S. M. (2013). Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus. Expert. Opin. Investig. Drugs 22, 463-486. doi: 10.1517/13543784.2013.774372
42. Wolf, S., Rave, K., Heinemann, L., and Roggen, K. (2009). Renal glucose excretion and tubular reabsorption rate related to blood glucose in subjects with type 2 diabetes with a critical reappraisal of the "renal glucose threshold" model. Horm. Metab. Res. 41, 600-604. doi: 10.1055/s-0029-1220723
43. Wright, E. M. (2001). Renal Na(+)-glucose cotransporters. Am. J. Physiol. Renal. Physiol. 280, F10-F18. Available online at: http://ajprenal.physiology.org/content/280/1/F10
44. Yamaguchi, K., Kato, M., Ozawa, K., Kawai, T., Yata, T., Aso, Y., et al. (2012). Pharmacokinetic and pharmacodynamic modeling for the effect of sodium-glucose cotransporter inhibitors on blood glucose level and renal glucose excretion in db/db mice. J. Pharm. Sci. 101, 4347-4356. doi: 10.1002/jps.23302
45. Yamaguchi, K., Kato, M., Suzuki, M., Asanuma, K., Aso, Y., Ikeda, S., et al. (2011). Pharmacokinetic and pharmacodynamic modeling of the effect of an sodium-glucose cotransporter inhibitor, phlorizin, on renal glucose transport in rats. Drug Metab. Dispos. 39, 1801-1807. doi: 10.1124/dmd.111.040048
46. Yu, L., Lv, J. C., Zhou, X. J., Zhu, L., Hou, P., and Zhang, H. (2011). Abnormal expression and dysfunction of novel SGLT2 mutations identified in familial renal glucosuria patients. Hum. Genet. 129, 335-344. doi: 10.1007/s00439-010-0927-z
47. Zambrowicz, B., Ding, Z. M., Ogbaa, I., Frazier, K., Banks, P., Turnage, A., et al. (2013). Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes. Clin. Ther. 35, 273-285. doi: 10.1016/j.clinthera.2013.01.010